What is retatrutide?
Retatrutide (LY3437943) is a single peptide that acts at three receptors at once — GIP, GLP-1 and glucagon. What that means, what has been studied, and what has not.
Retatrutide, development code LY3437943, is a synthetic peptide agonist at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor and the glucagon receptor. It belongs to the class the literature now calls multi-receptor or "triple" agonists, alongside the dual GIP/GLP-1 agonist tirzepatide [5]. It is not approved anywhere and is available, outside trials, only as a research material.
The pathway family is incretin signalling plus glucagon: the first two receptors are the axis semaglutide and tirzepatide work on, and the third is the one that distinguishes retatrutide from both.
Research Studies
Retatrutide and the multi-receptor design
A 2026 review of obesity pharmacotherapy describes the move from single-receptor GLP-1 agonists to dual and triple agonists as a deliberate attempt to add mechanisms rather than dose [5]. Retatrutide is the leading example of the triple design. The review is a survey of the field, not a trial, and should be read as such.
Retatrutide and metabolic dysfunction-associated steatotic liver disease
A 2026 animal study reported multiple metabolic effects of retatrutide in diet-induced obese mouse and hamster models of metabolic dysfunction-associated steatohepatitis [6]. The population was rodents; the outcomes were metabolic and hepatic markers in those models. It is one of the few papers in this pool about the compound itself rather than the class.
Retatrutide and the incretin class in liver disease
A broader 2026 review considers incretin receptor agonists as a class in steatotic liver disease and places retatrutide among the agents under investigation [4]. Again a review: it collects what has been reported and says where the evidence is thin.
Retatrutide and expanded access
A pre-approval expanded-access programme for retatrutide is registered on ClinicalTrials.gov [1]. Expanded access is not a trial and produces no efficacy data; its existence tells you only that a sponsor is supplying the molecule outside trials under a defined protocol.
Retatrutide and class-wide adverse reports
A 2026 data-mining analysis examined dysesthesia reports associated with GLP-1 agonist therapies as a class [2]. It does not single out retatrutide, and pharmacovigilance mining establishes signals rather than causes, but it is the kind of paper a careful reader wants in front of them when the class is discussed.
Retatrutide and what is not known
The human evidence in this pool is registrations and reviews; the mechanistic work is animal. Nothing here establishes efficacy or a safety profile in people outside a sponsor's trials, and this page does not claim otherwise. The questions the reviews leave open are the ones a reader should carry to any other source: how much of the effect each receptor accounts for, how the compound behaves over long exposure, and whether the rodent liver findings hold in people. A page that answers them confidently is ahead of the literature it cites.
Retatrutide and the glucagon receptor
The third receptor is the one that sets the design apart, and it is the one that makes the class harder to reason about. Glucagon signalling raises hepatic glucose output — the opposite of what an incretin agonist is usually asked to do — while also increasing energy expenditure and hepatic fat oxidation in the models where it has been examined. The multi-receptor reviews in this pool describe the design intent as balancing those effects rather than avoiding one of them [5], and the animal work reports the net metabolic picture in rodents rather than isolating each receptor's share [6]. Which receptor contributes what, in which tissue, is an open question the literature states rather than answers.
Retatrutide and tirzepatide
Tirzepatide is the nearest relative: a dual agonist at the GIP and GLP-1 receptors, and an approved product. Retatrutide adds glucagon receptor activity to that pair. The reviews treat the two as successive steps in the same programme of adding receptors to a single peptide backbone [4][5]. For a research buyer the relevance is practical: the two are structurally close enough that only mass spectrometry distinguishes a vial of one from a vial of the other, and a certificate that reports purity without identity does not tell them apart.
Retatrutide and the animal models in the pool
The one primary study of the compound itself in this evidence block used two rodent models of diet-induced obesity with steatohepatitis — mouse and hamster — and reported changes in body weight, glycaemic markers and liver histology under retatrutide [6]. Two models rather than one is a strength the authors note; the limitation they also note is that neither is a human liver. The review literature treats such results as the reason the class is in human trials, not as a substitute for them [4][5].
Retatrutide and its identifiers
The development code LY3437943 is the identifier that appears in registrations and early literature [1]; "retatrutide" is the international non-proprietary name assigned later. Both refer to the same molecule, and a certificate or a paper may use either. A search of the registry under one name will miss entries filed under the other, which is why the evidence pool for this page was assembled under both.
Retatrutide and the research material
As supplied for research, retatrutide is a lyophilised powder with a per-batch analytical report. The identity question matters more here than for most compounds: a triple agonist, a dual agonist and a single agonist can all be white powder in a 5 mg vial, and only mass spectrometry tells them apart.
| Compound | Receptors | Status in this pool |
|---|---|---|
| Semaglutide | GLP-1 | Approved product; trials registered |
| Tirzepatide | GIP, GLP-1 | Approved product |
| Retatrutide | GIP, GLP-1, glucagon | Investigational; animal data and reviews |
If you are reading this for personal health reasons
Everything on this page describes material sold for laboratory research. Peptides Pro does not provide dosing or medical guidance, and nothing here should be read as either. Anyone considering a compound for their own use should speak to a licensed clinician.
Sources
- [1] Pre-approval Expanded Access of Retatrutide (LY3437943). ClinicalTrials.gov, 2026. https://clinicaltrials.gov/study/NCT07629401
- [2] Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models.. europe_pmc, 2026. https://europepmc.org/article/PMC/PMC13250738
- [4] A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight. ClinicalTrials.gov, 2025. https://clinicaltrials.gov/study/NCT07232719
- [5] A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia. ClinicalTrials.gov, 2025. https://clinicaltrials.gov/study/NCT06982846
- [6] A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus. ClinicalTrials.gov, 2025. https://clinicaltrials.gov/study/NCT06982859